
COO Stock Declines Despite Strong Core Growth Amid Fertility Woes
The Cooper Companies grows margins and premium products, but fertility softness, inventory cuts, and tariffs weigh on the near-term outlook.
Predicted Price is the pryogiTM prediction of where the price is going in next 3-4 quarters. There may be a revision of the predicted price every 3 months from the date of publication of the first predicted price of the stock. Price on Report Date is the price of the stock on the day prediction was published by pryogiTM. Current price shows the current price of the stock.
Margin of error shows range the price will end up in dollars either above or below the predicted price. Margin of error percentage shows the price will end up in percentage either above or below the predicted price.
Expected Returns from report date shows the returns (positive or negative) from published prediction date if you bought the stock on report date. Expected Returns from today shows the returns from today if you buy the stock today. A positive expected returns indicates a profit you will make, a negative expected return indicates a loss you will make if you buy the stock. There are different strategies to apply in the stock market for profit and loss, pryogiTM will publish such strategies in the future to help you.
PryogiTM meter shows you predicted price, price on the date this prediction was published(report date) and price of the stock today on a price scale. This indicates if the stock price is moving towards or away from the predicted price
PryogiTM performance chart shows actual movement of stock price from prediction published date(report date) and if the price is moving towards or away from predicted price
The Cooper Companies grows margins and premium products, but fertility softness, inventory cuts, and tariffs weigh on the near-term outlook.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Needham analyst David Saxon upgraded the rating for The Cooper Companies, Inc.
Explore The Cooper Companies' (COO) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Cooper Companies beats fiscal second-quarter estimates and raises guidance, but faces fertility headwinds and inventory pressures. Is COO still a long-term growth play?
XRAY vs. COO: Which Stock Is the Better Value Option?
COO's fiscal Q2 earnings and sales beat market expectations on the back of strong growth. Improvement in operating margin bodes well.
U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Friday. Shares of Elastic N.V. ESTC fell sharply in today's pre-market trading after the company reported fourth-quarter results. Elastic posted adjusted earnings of 47 cents per share, beating market ...
The Cooper Companies (COO) delivered earnings and revenue surprises of 3.23% and 0.67%, respectively, for the quarter ended April 2025. Do the numbers hold clues to what lies ahead for the stock?
COO benefits from the strength in its business segments. Its acquisitions are likely to drive the top line. However, a rise in selling, general and administrative expenses is concerning.
Evaluate the expected performance of The Cooper Companies (COO) for the quarter ended April 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
COO's fiscal second-quarter results are expected to follow seasonal trends, with a lighter start compared to the previous two reported quarters.
Zomedica (ZOMDF) delivered earnings and revenue surprises of -100% and 16.45%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
XRAY vs. COO: Which Stock Is the Better Value Option?
Dentsply (XRAY) delivered earnings and revenue surprises of 48.28% and 3.22%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Staar Surgical (STAA) delivered earnings and revenue surprises of 11.86% and 5.57%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Cardinal (CAH) delivered earnings and revenue surprises of 9.30% and 0.27%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
COO's top line fails to meet market expectations despite recording strong growth. However, improvement in operating margin bodes well.
The Cooper Companies (COO) delivered earnings and revenue surprises of 0% and 1.71%, respectively, for the quarter ended January 2025. Do the numbers hold clues to what lies ahead for the stock?
COO's fiscal first-quarter results are expected to follow seasonal trends, with a lighter start compared to the previous two reported quarters.
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for The Cooper Companies (COO), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended January 2025.
Dentsply (XRAY) delivered earnings and revenue surprises of -39.53% and 1.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Patterson Cos. (PDCO) delivered earnings and revenue surprises of -30.65% and 3.81%, respectively, for the quarter ended January 2025. Do the numbers hold clues to what lies ahead for the stock?
Align Technology (ALGN) delivered earnings and revenue surprises of 0.41% and 0.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
The continued solid uptake of BD's products is expected to have driven fiscal first-quarter revenues despite transitory market dynamics.
COO benefits from strength in its business segments. Its acquisitions are likely to drive the top line. However, a rise in selling, general and administrative expenses is concerning.
Investors need to pay close attention to Cooper Companies (COO) stock based on the movements in the options market lately.
On CNBC's "Mad Money Lightning Round," Jim Cramer said Occidental Petroleum OXY is one of his "least favorite oils."
SAN FRANCISCO, Dec. 11, 2024 ( GLOBE NEWSWIRE ) -- On December 4, 2024, Judge Jon S. Tigar of the U.S.
Explore how The Cooper Companies' (COO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
COO's top line fails to meet market expectations despite recording strong growth. However, improvement in operating margin bodes well.
The Cooper Companies (COO) delivered earnings and revenue surprises of 4% and 0.89%, respectively, for the quarter ended October 2024. Do the numbers hold clues to what lies ahead for the stock?
COO's fiscal fourth-quarter results are likely to reflect segmental strength.
Besides Wall Street's top -and-bottom-line estimates for The Cooper Companies (COO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended October 2024.
PDCO's fiscal second-quarter results are likely to reveal a decline in both the Dental and Animal Health segments, reflecting challenges like moderating traffic to clinics.
Ocugen (OCGN) delivered earnings and revenue surprises of 0% and 5.33%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
biote Corp. (BTMD) delivered earnings and revenue surprises of 266.67% and 0%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
COO benefits from strength in its business segments. Its acquisitions are likely to drive the top line. However, a rise in selling, general and administrative expenses is concerning.
Becton Dickinson (BDX) delivered earnings and revenue surprises of 1.06% and 1.59%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
GKOS continues to benefit from a robust demand for its products and expansion in new markets. A strong development pipeline raises optimism.
DVA's strength in its kidney care business raises optimism about the stock.
BD's robust product portfolio and a few strategic deals raise optimism about the stock. However, stiff competition and macroeconomic volatility are concerns.
COO benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.
Lewes, Delaware, Oct. 01, 2024 ( GLOBE NEWSWIRE ) -- The Global Trocars Market Size is projected to grow at a CAGR of 6.1% from 2024 to 2031, according to a new report published by Verified Market Research®.
XRAY continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include BDX, MCK, COO and STAA.
Does The Cooper Companies (COO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Hedge fund managers sit on the boards of Bausch Health and Bausch + Lomb. They don't think like your typical corporate board, writes Ken Squire of 13D Monitor.
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?